Trial Outcomes & Findings for Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors (NCT NCT02956291)
NCT ID: NCT02956291
Last Updated: 2026-08-25
Results Overview
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
COMPLETED
NA
170 participants
At end of scan (45 minutes after beginning study)
2026-08-25
Participant Flow
Participant milestones
| Measure |
Experimental: Total Number of Scans
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
Overall Study
STARTED
|
170
|
|
Overall Study
COMPLETED
|
149
|
|
Overall Study
NOT COMPLETED
|
21
|
Reasons for withdrawal
| Measure |
Experimental: Total Number of Scans
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
Overall Study
Withdrawal by Subject
|
19
|
|
Overall Study
Lost to Follow-up
|
2
|
Baseline Characteristics
Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors
Baseline characteristics by cohort
| Measure |
Experimental: Total Number of Scans
n=170 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
Age, Customized
20-29 years
|
8 Participants
n=31 Participants
|
|
Age, Customized
30-39 years
|
11 Participants
n=31 Participants
|
|
Age, Customized
40-49 years
|
20 Participants
n=31 Participants
|
|
Age, Customized
50-59 years
|
45 Participants
n=31 Participants
|
|
Age, Customized
60-69 years
|
50 Participants
n=31 Participants
|
|
Age, Customized
70-79 years
|
30 Participants
n=31 Participants
|
|
Age, Customized
80-89 years
|
4 Participants
n=31 Participants
|
|
Age, Customized
90-99 years
|
2 Participants
n=31 Participants
|
|
Sex: Female, Male
Female
|
76 Participants
n=31 Participants
|
|
Sex: Female, Male
Male
|
94 Participants
n=31 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=31 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
169 Participants
n=31 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=31 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Black or African American
|
11 Participants
n=31 Participants
|
|
Race (NIH/OMB)
White
|
156 Participants
n=31 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=31 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=31 Participants
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, and 39 participants had prior treatment, therefore of the 170 participants in the baseline population, only 78 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=78 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group A: High Grade Glioma
|
1774.57 Milliseconds (ms)
Standard Deviation 204.54
|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group B: Low Grade Glioma
|
1908.31 Milliseconds (ms)
Standard Deviation 273.65
|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group C: Brain Metastasis
|
1722.56 Milliseconds (ms)
Standard Deviation 197.25
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, and 39 participants had prior treatment, therefore of the 170 participants in the baseline population, only 78 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=78 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group A: High Grade Glioma
|
98.88 Milliseconds (ms)
Standard Deviation 20.95
|
|
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group B: Low Grade Glioma
|
114.07 Milliseconds (ms)
Standard Deviation 30.67
|
|
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group C: Brain Metastasis
|
87.59 Milliseconds (ms)
Standard Deviation 28.01
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 27 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 51 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=51 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Tumor Type
Group A: High Grade Glioma
|
974.03 Milliseconds (ms)
Standard Deviation 309.57
|
|
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Tumor Type
Group B: Low Grade Glioma
|
1558.47 Milliseconds (ms)
Standard Deviation 324.97
|
|
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Tumor Type
Group C: Brain Metastasis
|
833.57 Milliseconds (ms)
Standard Deviation 238.65
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 27 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 51 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=51 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group A: High Grade Glioma
|
88.23 Milliseconds (ms)
Standard Deviation 20.75
|
|
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group B: Low Grade Glioma
|
109.205 Milliseconds (ms)
Standard Deviation 39.63
|
|
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Tumor Type
Group C: Brain Metastasis
|
86.43 Milliseconds (ms)
Standard Deviation 26.13
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 25 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 53 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=53 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group A: High Grade Glioma
|
1714.13 Milliseconds (ms)
Standard Deviation 208.407
|
|
T1 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group C: Brain Metastasis
|
1677.61 Milliseconds (ms)
Standard Deviation 229.44
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 25 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 53 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=53 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T2 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group A: High Grade Glioma
|
107.12 Milliseconds (ms)
Standard Deviation 26.81
|
|
T2 Pre-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group C: Brain Metastasis
|
109.55 Milliseconds (ms)
Standard Deviation 30.44
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 42 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 36 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=36 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group A: High Grade Glioma
|
1508.35 Milliseconds (ms)
Standard Deviation 316.51
|
|
T1 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group C: Brain Metastasis
|
1457.83 Milliseconds (ms)
Standard Deviation 275.51
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 42 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 36 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=36 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T2 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group A: High Grade Glioma
|
105.09 Milliseconds (ms)
Standard Deviation 29.05
|
|
T2 Post-contrast Relaxometry Value of Peritumoral White Matter in MRF Scan for Each Tumor Region
Group C: Brain Metastasis
|
112.78 Milliseconds (ms)
Standard Deviation 33.23
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 27 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 51 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=51 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group B: Glioma Grade 2
|
1968.83 Milliseconds (ms)
Standard Deviation 325.07
|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group A1: Glioma Grade 3
|
1861.61 Milliseconds (ms)
Standard Deviation 238.06
|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group A2: Glioma Grade 4
|
1774.57 Milliseconds (ms)
Standard Deviation 204.54
|
PRIMARY outcome
Timeframe: At end of scan (45 minuets after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 27 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 51 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=51 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group B: Glioma Grade 2
|
119.09 Milliseconds (ms)
Standard Deviation 36.814
|
|
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group A1: Glioma Grade 3
|
105.602 Milliseconds (ms)
Standard Deviation 25.67
|
|
T2 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group A2: Glioma Grade 4
|
98.88 Milliseconds (ms)
Standard Deviation 20.95
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 47 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 31 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=31 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Glioma Tumor Grade
Group B: Glioma Grade 2
|
1805.17 Milliseconds (ms)
Standard Deviation 334.17
|
|
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Glioma Tumor Grade
Group A1: Glioma Grade 3
|
1283.12 Milliseconds (ms)
Standard Deviation 323.52
|
|
T1 Post-contrast Relaxometry Value of Solid Tumor Region in MRF Scan for Each Glioma Tumor Grade
Group A2: Glioma Grade 4
|
974.03 Milliseconds (ms)
Standard Deviation 309.57
|
PRIMARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 47 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 31 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=31 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group B: Glioma Grade 2
|
119.65 Milliseconds (ms)
Standard Deviation 43.46
|
|
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group A1: Glioma Grade 3
|
104.78 Milliseconds (ms)
Standard Deviation 29.56
|
|
T2 Post-contrast Relaxometry Value of Solid Tumor in MRF Scan for Each Glioma Tumor Grade
Group A2: Glioma Grade 4
|
88.23 Milliseconds (ms)
Standard Deviation 20.75
|
SECONDARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 29 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 49 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=49 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for IDH1 Mutations in Glioma Tumor
Group AB1: IDH1 Mutant
|
1835.33 Milliseconds (ms)
Standard Deviation 266.96
|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for IDH1 Mutations in Glioma Tumor
Group AB2: IDH1 Wild type
|
1816.53 Milliseconds (ms)
Standard Deviation 224.77
|
SECONDARY outcome
Timeframe: At end of scan (45 minutes after beginning study)Population: Two participants were lost to follow-up, 19 participants did not complete the scan, 7 scans were corrupted, 4 participants did not have tissue diagnosis, 21 participants had non-tumor pathology, \& 39 participants had prior treatment. 30 participants were not included based on applicable tumor type/region, grade, \& genetic markers. Therefore, of the 170 baseline participants, only 48 participants were included in this outcome measure analysis, divided into meaningful sub-groups for analysis.
Relaxometry time is the measurement of relaxation times from MR images and is the quantitative imaging technique that measures the exact T1 and T2 times of tissue.: T1 and T2 are imaging sequences. T1 is used for visualizing clear anatomy and fat, while T2 is used for detecting inflammation, edema and fluid buildup.
Outcome measures
| Measure |
Experimental: Total Number of Scans
n=48 Participants
This arm includes participants who have high grade glioma, low grade glioma, or brain metastasis. Participants in this arm underwent Magnetic Resonance Fingerprinting (MRF) scan along with their clinical scan, followed by standard of care surgery, radiation, and chemotherapy. Follow-up MRF scans were performed to visualize recurrence and/or as deemed appropriate by the treating physician.
|
|---|---|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for ATRX Mutations in Glioma Tumor
Group AB3: ATRX Mutant
|
1969.45 Milliseconds (ms)
Standard Deviation 335.13
|
|
T1 Pre-contrast Relaxometry Value of Solid Tumor in MRF Scan for ATRX Mutations in Glioma Tumor
Group AB4: ATRX Positive
|
1797.65 Milliseconds (ms)
Standard Deviation 230.52
|
Adverse Events
Experimental: Total Number of Scans
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Principal Investigator, Chaitra Badve, MD
University Hospitals, Case Comprehensive Cancer Center
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place